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Summary
Heart valve tissue engineering holds the potential to over-
come limitations of currently used heart valve prostheses.
It involves the isolation and expansion of autologous pa-
tient cells, the subsequent seeding of these cells onto an
appropriate scaffold material, the in vitro incubation and
the in vivo implantation of the derived tissue-engineered
construct into the patient from whom the cells were taken.
While vascular-derived cells require harvest of intact donor
tissue and show limited expansion capacities, the use of
stem or progenitor cells may overcome these limitations
and expand the versatility of the concept of heart valve
tissue engineering. Possible sources include cells isolated
from blood, bone marrow, adipose tissue, amniotic fluid,
chorionic villi, umbilical cord and induced pluripotent stem
cells. Here we review different stem cell sources with par-
ticular regard to cellular phenotypes and their suitability for
application in heart valve tissue engineering.
Keywords: heart valve tissue engineering; regenerative
medicine; stem cells; bone marrow; amniotic fluid;
umbilical cord
Introduction
In valvular heart ailments the global disease load is over-
whelming and will substantially increase in the near future.
Approximately 290,000 heart valve replacements are per-
formed globally per year and the number of patients requir-
ing heart valve replacement is expected to triple by the year
2050 [1]. Despite the major advances in surgical treatment,
valvular heart disease thus remains one of the outstanding
causes of morbidity and mortality round the globe [1–3].
Although the currently used valvular prostheses provide
adequate short-term performance, prosthesis-related com-
plications are reported in up to 50% of heart valve re-
cipients 10–15 years after the operation [4]. While mech-
anical prostheses require lifelong anticoagulation therapy,
bioprosthetic substitutes are inherently prone to progress-
ive calcification and valvular degeneration. None of the
currently used non-viable valve replacements hold poten-
tial for remodelling, regeneration and/or growth.
Cardiovascular tissue engineering has therefore evolved as
an interdisciplinary field applying the principles of engin-
eering to the development of biological substitutes that can
restore, maintain or improve these impaired or diseased
cardiovascular structures [1–3, 5]. According to this pre-
definition two basic strategies have been developed to gen-
erate living autologous valvular replacements [5]. The first
requires an in-vitro phase generating the valvular substitute
ex vivo. This “classical” tissue engineering paradigm in-
cludes isolation and expansion of autologous patient cells,
subsequent seeding of these cells onto an appropriate scaf-
fold material, in-vitro tissue formation and, finally, im-
plantation of the construct into the patient from whom the
cells were taken. This paradigm, which is further referred
to as the ‘in vitro tissue engineering’ approach, has been
employed as the major approach for heart valve tissue en-
gineering over the last decade and primarily aims at full
development of native-like tissue substitutes ex vivo. The
second approach of “in situ heart valve tissue engineering”
circumvents the extensive in vitro tissue culture phase by
straight implantation of polymeric or natural tissue-derived
heart valve matrices that are pre-seeded with autologous
cells and principally aim at potential host cell attraction and
subsequent remodelling in vivo. This approach has aroused
major interest in the last few years and also brought the ini-
tiation of first human clinical trials for vascular grafts in the
United States [6–7].
Stem cells as a potential cell source
for cardiovascular tissue engineering
Initially, heart valve tissue engineering involved the isol-
ation of cells harvested from vascular donor tissues, in-
cluding peripheral arteries, where mixed vascular cell pop-
ulations were obtained for seeding [1–2, 8]. Out of those,
two principal cell lines could be isolated: endothelial cells
forming a confluent endothelial cell lining on the surface
with antithrombogenic features, and myofibroblast-like
cells responsible for the extracellular matrix development
of the bioengineered constructs [9]. While isolation of
these cells was technically simple and these cells have re-
peatedly demonstrated substantial tissue formation capa-
city in vitro, the use of vascular-derived cells is also associ-
ated with certain fundamental shortcomings. Cell harvest-
ing prior to seeding requires the sacrifice of intact vascular
donor tissues, which constitutes a considerable limitation,
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in particular for paediatric applications. In addition, cardi-
ovascular risk factors and co-morbidities such as diabetes
mellitus and atherosclerosis may cause endothelial dys-
function [10] and thus influence the consistence of vessel-
derived cell layers. To avoid the sacrifice of healthy human
vascular structures and circumvent additional surgical in-
terventions, several different stem cell sources have been
investigated with regard to their use in cardiovascular tis-
sue engineering, in particular for heart valves. The com-
mon defining properties of stem cells are (1.) self-renewal
in clonogenic conditions and (2.) potential for differenti-
ation into several lineages [11]. Hence, besides avoiding la-
ceration of intact vascular donor tissue, stem and/or pro-
genitor cells could also be associated with several advant-
ages, i.e. (1.) they have the potential to differentiate into
multiple cell lineages in vivo under a certain biochemical
and mechanical stimulation, (2.) they display unique im-
munological characteristics allowing persistence in allo-
geneic settings, but also mediating the attraction of repar-
ative host immune and/or progenitor cells, and (3.) they
Figure 1
Available stem cells for heart valve tissue engineering. (A: Donor
tissues and stem cell sources, B: Introduction of the cells into the in
vitro heart valve tissue engineering procedure; 1: cell isolation,
2: cell expansion, 3: seeding of cells onto the scaffold, 4: dynamic
conditioning of the construct in a bioreactor system, 5: possible
implantation of the deriving construct into the patient).
exhibit extensive in vitro proliferation capacity demonstrat-
ing their stem cell nature [2–3].
In particular, in paediatric patients prenatally harvested
stem cells derived from the foetus could allow a novel
therapeutic concept of “paediatric heart valve tissue en-
gineering” in the future. This approach primarily aims at
the fabrication of living, autologous, growing replacements
for the repair of congenital malformations even before or
shortly after birth. For this purpose cells are ideally ob-
tained during pregnancy or perinatally from the foetal “ad-
nexa”. Several recent investigations have addressed this
issue of finding the appropriate prenatal cell source for
this novel concept. In particular, umbilical cord-derived
cells, amniotic fluid-derived cells and chorionic villi-de-
rived cells are among the most promising candidates under
investigation. Besides these foetus-derived adult stem cells,
several other stem cell sources have been investigated with
regard to their potential use in heart valve tissue engineer-
ing (fig. 1; table 1). In the following we provide a compre-
hensive overview and summary of the potential stem cells
used and the principal techniques involved.
Available sources of stem cells for
heart valve tissue engineering
Bone marrow-derived mesenchymal stem cells
Aside from stem and/or progenitor cells of different haema-
topoietic lineages, the bone marrow is known to be a source
of cells fulfilling criteria for stem cells of non-haematopoi-
etic tissue. These bone marrow-derived non-haematopoi-
etic stem cells have been widely employed as a potential
cell source for cardiovascular regeneration in general [12].
While these cells are considered multipotent, they are also
referred to as either “mesenchymal stem cells” (MSCs), be-
cause of their ability to differentiate into different pheno-
types of the mesoderm germ layer, including fat, bone and
cartilage, or as “marrow stromal cells” as they appear to
arise from the complex array of supporting structures found
in the marrow stroma [13].
These cells have also been investigated as a possible cell
source for the in vitro fabrication of cardiovascular substi-
tutes in vitro [14]. Hoerstrup et al. [15] then successfully
used human bone marrow-derived MSCs (BM-MSCs) for
the fabrication of living trileaflet heart valves in vitro,
while Sutherland et al. [16] also demonstrated initial sat-
isfactory in vivo performance as pulmonary valve substi-
tutes. Recently, the combination of autologous BM-MSC-
Table 1: Available stem cell sources for heart valve tissue engineering.
Stem cell source Isolated phenotypes Reference
Bone marrow Mesenchymal stem cells [15–17]
Bone marrow mononuclear cells [23]
Blood Endothelial progenitor cells [17]
Adipose tissue Mesenchymal stem cells [26, 27]
Amniotic fluid Mesenchymal stem cells [34, 35]
Endothelial progenitor cells [34, 35]
Chorionic villi Mesenchymal stem cells [38]
Umbilical cord matrix Mesenchymal stem cells [44]
Umbilical cord blood Mesenchymal stem cells [40]
Endothelial progenitor cells [44]
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derived tissue engineered heart valves with a minimally
invasive stent-based implantation technique has also been
investigated in vivo in the ovine model [17].
Bone marrow-derived mononuclear cells
Apart from using adherent fractions of bone marrow cells,
represented by the multipotent MSCs, the option of using
unsorted bone marrow mononuclear cells (BMCs) in total
for the technique of in situ tissue engineering has recently
Figure 2
Bone marrow mononuclear cell-based tissue engineered heart
valve prior to implantation into an animal model. (Reprinted from
[23]: Weber B, Scherman J, Emmert MY, Gruenenfelder J, Verbeek
R, Bracher M, et al. Injectable living marrow stromal cell-based
autologous tissue engineered heart valves: first experiences with a
one-step intervention in primates. Eur Heart J.
2011;32(22):2830–40. © Oxford University Press, Oxford, UK, with
kind permission.)
Figure 3
Histomorphology of a chorionic villus showing the outer
trophoblastic coverage surrounding the inner foetal mesenchyme
also comprising the foetal capillaries (black arrows). (Reprinted
from: Weber B, Zeisberger SM, Hoerstrup SP. Prenatally harvested
cells for cardiovascular tissue engineering: Fabrication of
autologous implants prior to birth. Placenta. 2011;32(Suppl.
4):S316–9. © Elsevier, Oxford, UK, with kind permission).
had a major impact on the field of cardiovascular tissue en-
gineering, and also given promising initial clinical results
in Japan [18]. This was further stimulated by the recent ini-
tiation of a clinical trial in the USA [6–7], mainly aiming at
autologous cell-based vascular repair in infants with con-
genital heart defects.
This principle of using BMCs for cardiovascular tissue en-
gineering was first described by Shin’oka et al. and has
been extensively assessed in experimental [19–20] as well
as clinical [18, 21] investigations. Initially it was hypo-
thesised that the contained fraction of multipotent bone
marrow-derived stem cells (BM-MSCs) would proliferate
and constitute new tissues on the bioengineered constructs
[19]. However, Roh et al. [20] showed that initially seeded
BMCs disappear from the scaffolds within days and no dif-
ferentiation of mesenchymal stem cells into valvular in-
terstitial cells may be observed. In fact, they showed that
the potential underlying molecular mechanism is a BMC-
mediated inflammation-driven process of vascular remod-
elling via a paracrine role of pre-seeded BMCs, which is
consistent with multiple studies reporting that (trans-) dif-
ferentiation of bone marrow-derived mesenchymal stem
cells in vivo is deemed rare [22–23].
While Shin’oka et al. mainly focused on the repair of blood
vessels [18–21], Weber et al. [23] recently for the first time
applied the BMC-based in situ technique to the repair of
heart valves (fig. 2). After seeding of matrices with auto-
logous BMCs in vitro, the tissue engineered heart valves
were implanted in vivo and evaluated in a large clinically
relevant animal model with promising initial results.
Figure 4
Human umbilical cord Wharton’s jelly-derived myofibroblast-like
cells (WMFs) revealed smooth muscle-like phenotypes with positive
stainings for vimentin (C), desmin (E) and partially for α-sma (A)
similar to mature vascular-derived myofibroblasts (B, D, F).
(Reprinted from [48]: Weber B, Schoenauer R, Papadopulos F,
Modregger P, Peter S, Stampanoni M, et al. Engineering of living
autologous human umbilical cord cell-based septal occluder
membranes using composite PGA-P4HB matrices. Biomaterials.
2011;32(36):9630–41. © Elsevier, Oxford, UK, with kind
permission.)
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Adipose tissue-derived mesenchymal stem cells
Adipose tissue has been shown to contain mesenchymal
stem cells that can differentiate into various phenotypes in
vitro [24]. As to the high availability of this source of tis-
sue and because it can be obtained in fairly large quantit-
ies with low invasive techniques (e.g., liposuction), adipose
tissue-derived multipotent stem cells (ADSCs) have been
considered as a potential alternative to bone marrow-de-
rived mesenchymal stem cells in the future [25]. Besides
their mesenchymal phenotype, several studies demon-
strated that ADSCs show characteristics of endothelial pro-
genitor cells (EPCs), express endothelial specific markers
in vitro when cultured with VEGF, and hold the potential
to differentiate into endothelial cells in vivo, which also
seems important with regard to heart valve tissue engineer-
ing applications [26]. In a first attempt Colazzo et al. [27]
investigated the use of ADSCs for heart valve tissue engin-
eering in vitro with promising initial results concerning the
formation of collagen and elastin.
Peripheral blood-derived endothelial progenitor cells
Multiple investigations have demonstrated that the presen-
ce of endothelium on cardiovascular surfaces may signi-
ficantly reduce the risk of coagulation and inflammatory
complications as well as playing an intricate role for proper
valvular functionality in general [28]. Hence in order to
improve the functional capacities, the tissue engineered
heart valve constructs are usually covered with a layer
of autologous endothelial cells (ECs [29]). Fully matured
ECs have been successfully isolated from different vascu-
lar donor tissues and used in heart valve tissue engineering
[2–3, 8–9]. However, despite the importance of ECs, ma-
ture vascular-derived ECs have been associated with sev-
eral shortcomings including a relatively slow expansion
rate and limited proliferation capacity [30]. Beyond that,
the harvest of mature ECs from donor vessels requires an
invasive harvest procedure, potentially associated with an
evident risk for the donor, finding a source of rapidly pro-
liferating and ready-to-use ECs not requiring harmful sur-
gical harvest procedures would therefore be advantageous.
First discovered in human peripheral blood by Asahara et
al. [31], endothelial progenitor cells (EPCs), have been in-
vestigated as a possible alternative source of ECs. Isolated
from the blood, these progenitor cells constitute a highly at-
tractive alternative cell source of ECs, as they can easily be
isolated from peripheral blood, bone marrow and umbilical
cord blood ([2–3]; for umbilical cord-blood derived EPCs
see also below).
In a first attempt, Schmidt et al. isolated EPCs from adult
peripheral blood in an ovine model, which were then
seeded onto tissue engineered heart valves and re-im-
planted in vivo [17].
Amniotic fluid-derived mesenchymal stem cells
Amniotic fluid represents an attractive foetal cell source
for the concept of paediatric heart valve tissue engineering
since it renders possible prenatal access to foetal cells from
all three germ layers via a low-risk procedure [32]. Several
studies have shown promising initial results based on hu-
man amniotic fluid-derived mesenchymal stem cells in re-
lation to non-cardiovascular tissue engineering [33].
In 2007, Schmidt et al. demonstrated the feasibility of gen-
erating living autologous heart valve leaflets in vitro using
human amniotic fluid as a single cell source. This also in-
volved isolation of mesenchymal-like progenitor cells us-
ing the MACS-sorting technique [34]. To expand the ver-
satility and clinical applicability of this cell source also,
cryopreserved amniotic fluid-derived mesenchymal cells
were investigated as a potential life-long cell source [35].
These experiments showed that freshly isolated as well as
cryopreserved amniotic fluid-derived cells can be success-
fully used to fabricate endothelialised tissue engineered
heart valves in vitro. In spite of these promising results,
several concerns possibly related to this cell source, such
as carcinogenicity (given the high plasticity), long-term ex-
pansion capacity and stable growth behaviour need to be
investigated in future studies.
Amniotic fluid-derived endothelial progenitor cells
Besides the mesenchymal cell lineages, several groups
have also reported on the successful isolation of
endothelial-like progenitor lineages sharing several simil-
arities of mature endothelial cells [32, 34–36]. Schmidt et
al. combined these endothelial phenotypes with the previ-
ously described amniotic fluid-derived MSCs for the fab-
rication of autologous endothelialised functional heart
valve leaflets [34–35].
Chorionic villi-derived mesenchymal stem cells
The human placenta is composed of a maternal and a foetal
portion. The foetal part, the chorionic villi (fig. 3), contain
extraembryonic mesenchymal tissue embedded between
the trophoblastic cells. These mesenchymal cells can be
isolated by chorionic villus sampling – a prenatal biopsy
technique for antenatal genetic diagnostics. Isolated from
a rather early developmental stage, these cells have been
shown to exhibit profound stem cell-like properties [37].
Schmidt et al. [38] first demonstrated the feasibility of this
approach for heart valve tissue engineering by using chor-
ionic villi-derived mesenchymal cells for the fabrication of
viable heart valve leaflets in vitro, with promising results.
Importantly, this extra-embryonic mesenchyme also con-
tains foetal capillary endothelial cells, which might also be
isolated using cell sorting techniques as part of future thera-
peutic concepts.
Umbilical cord blood-derived mesenchymal stem cells
Blood isolated from the umbilical cord pre- and/or peri-
natally represents a known reserve for adherently growing,
fibroblast-like cells, which render a similar immunophen-
otype as BM-MSCs characterised by the expression of
CD45-, CD13+, CD29+, CD73+, CD105+ [3, 39]. In the
light of these properties of UCB-derived MSCs and the
plethora of UCB-units already banked worldwide, UCB
could represent a potential future cell source for the isol-
ation of high numbers of MSCs required for heart valve
tissue engineering. Sodian et al. recently demonstrated the
fabrication of tissue engineered autologous heart valves
from CD133+ umbilical cord blood-derived cells with
stem-like properties as a single cell source [40].
However, recent investigations somewhat dampened exist-
ing hopes by making it clear that, when using unsepar-
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ated frozen CB units outgrowth of adherent cells from the
mononuclear fraction was poor and adherence to conven-
tional culture flasks seemed difficult [41].
Umbilical cord blood-derived endothelial progenitor
cells
Several studies have shown the feasibility of using human
umbilical cord blood-derived EPCs to generate constant
neo-endothelial phenotypes on tissue engineered cardi-
ovascular replacements [42–43]. In 2006, Schmidt et al.
also demonstrated the fabrication of biologically active liv-
ing heart valve leaflets when using prenatally available hu-
man umbilical cord-derived cells as the only cell source
[44]. Matrix stromal cells as well as umbilical cord blood-
derived EPCs were seeded onto biodegradable scaffolds
and cultured in a bio-mimetic system. The leaflets showed
mature layered tissue formation with functional neo-en-
dothelia and extracellular matrix production comparable
with that of native tissues, which convincingly demon-
strates the feasibility of using umbilical cord-derived pro-
genitor cells including EPCs for coverage of tissue engin-
eered heart valve leaflets in vitro.
Besides their use for surface endothelialisation, the out-
standing ease of harvesting and the favourable expansion
capacities of UCB-EPCs have also stimulated research on
their transdifferentiation into more mesenchymal/
myofibroblast-like phenotypes in order to provide new
strategies to guide tissue formation in engineered heart
valves and to render cord blood a feasible single source for
heart valve regeneration in the future.
Umbilical cord matrix-derived mesenchymal stem cells
The human umbilical cord represents a fundamental com-
ponent of the foetal circulation and is composed of two ar-
teries and one vein. These vessels are embedded in muc-
oid fetal mesenchymal tissue, which is often referred to
as “Wharton’s jelly”. Wang et al. [45] for the first time
identified mesenchymal cells within this matrix/jelly-tissue
expressing significant amounts of mesenchymal stem cell
(MSC) markers, suggesting the existence of mesenchymal
cells with stem-like properties. Subsequently, the presence
of these MSCs, termed umbilical cord matrix stromal cells
(UCMSCs, fig. 4), including their potential for multilin-
eage differentiation, has been confirmed, also indicating
that these UCMSCs may represent a promising cell source
for cell-based therapies involving cardiovascular tissue en-
gineering [46–47].
Several studies demonstrated the successful in vitro gener-
ation of living cardiovascular patches [42, 48], blood ves-
sels [43] and biologically active living heart valve leaflets
in vitro based on UCMSCs [44]. In 2006, Sodian et al. [49]
also demonstrated the use of cryopreserved human umbil-
ical cord cells (CHUCCs) for the in vitro fabrication of
tissue engineered heart valves expanding the versatility of
this cell source.
Induced pluripotent stem cells
Embryonic stem cells represent the “gold standard” for
stem cell research given their high differentiation potential
with the ability to differentiate into all three germ layers.
However, the ethical concerns associated with their
embryo-destructive harvesting as well as the induction of
tumour formation and immune-rejection in vivo have so
far limited their clinical use [50]. In their investigation
Takahashi et al. [51] introduced different combinations of
embryonic-development specific genes into mouse em-
bryonic fibroblasts and determined relevant factors neces-
sary to render a cell with differentiation potential into all
three germ layers. These factors could then be defined as
the minimum number of factors – mainly including OCT-3/
4, Sox-2, c-myc and KLF-4 – required for the generation of
induced pluripotent stem cells (iPS). The principal idea be-
hind this cellular reprogramming represents the possibility
of taking terminally differentiated cells, including e.g. skin
fibroblasts, and providing them with capacities of pluripo-
tent stem cells, including the possibility of giving rise to
any tissue of the body. Contrary to pluripotent cells de-
rived from the embryoblast of the blastocyst, iPS do not
raise ethical concerns associated with embryo-destruction
and may ultimately circumvent immunological rejection.
In the first attempt, Hibino et al. [52] fabricated cell sheets
from induced puripotent stem cells in a murine model,
which could be used for vascular tissue engineering. In
spite of the major hopes raised by these developments,
the potential carcinogenicity of virally transduced cells re-
mains a major obstacle for a clinical translation of this
concept. Even in non-virally transduced lines the occur-
rence of genome instability as well as evident epigenetic
memory of iPS are of concern and currently limit the clin-
ical feasibility of this approach [53]. In addition, recent
studies revealed that vascular cells derived from pluripo-
tent cells present with heterogeneous phenotypes and con-
sideration of in vivo developmental patterning might be be-
neficial for future in vivo differentiation approaches [54].
Besides the creation of iPS, the concept of direct repro-
gramming of one differentiated cell type into another
[55–56], which circumvents the fully pluripotent differen-
tiation state, may also have a major impact on the field of
vascular and valvular regeneration.
Alternative stem cell sources for future applications
In addition to the sources mentioned above, several further
stem cells have been identified that may principally hold
potential as a reserve of cells for heart valve tissue engin-
eering applications in the future. This includes cells from
other foetal and/or embryonic tissues such as cells from the
amniotic membrane. Also the spectrum of chorionic villi-
derived cells might be broadened by the isolation of the en-
dothelial fraction present in the foetal mesenchyme-derived
capillaries of secondary or tertiary chorionic villi. In addi-
tion, foetal progenitor cells have been found in the maternal
circulation, which may also be used for autologous foetal
cell-based therapies in the future.
For adult applications, several further stem cell sources
have not yet been applied to the heart valve tissue en-
gineering concept and might harbour great potential. This
includes transdifferentiated mesenchymal cells from en-
dothelial progenitor lines or blood-vessel-derived MSCs.
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Limitations
When dealing with stem cells there is a potential risk that
an uncontrolled growth or genetic alterations of these im-
mature cells might lead to tumour formation in vivo. In em-
bryonic stem cells as well as iPS this risk is most evident,
but also the risks of using other (non-pluripotent) stem cells
have not yet been fully evaluated. In addition, in the use of
biodegradable scaffolds, local inflammation and systemic
toxicity due to degradation products of biodegradable scaf-
folds represents a possible problem.
Hence, prior to clinical implementation of the stem cell-
based heart valve tissue engineering concept, systematic in-
vestigation in large animal studies is necessary to evaluate
long-term performance as well as principal safety of this
technology. In addition, systematic comparison of the in
vivo fate and function of TEHVs with the currently used
standard heart valve prosthesis technologies seems indis-
pensable.
Conclusions
In summary, several different stem / progenitor cell sources
are available and have been successfully integrated into
the tissue engineering workflow in vitro (table 1). This in-
cludes cells from the bone marrow, blood, adipose tissue,
amniotic fluid, placenta and umbilical cord. Besides these
‘adult’ stem cell sources, novel technologies exist to ‘re-
program’ a terminally differentiated somatic cell into a
stem-like cell by integrating specific genes into the cellular
genome, certainly representing a novel, highly promising
option for the future. Besides the plethora of existing stud-
ies on the use of these various cell sources for different
bioengineering applications, studies on a detailed compar-
ison of these sources with regard to factors such as ex-
pansion capacity, collagen formation, glycosaminoglycan
production, genomic stability or extracellular matrix re-
modelling, would be of fundamental importance. Although
these comparative approaches are an indispensable pre-
requisite for a future clinical translation, there are as yet
few studies on this aspect.
In addition, in vivo studies exist which provide us with the
first insight into the in vivo behaviour of the stem cell-
based therapeutic constructs. Although having these initial
impressions on remodelling and maturation of the bioen-
gineered tissues in vivo, knowledge on the actual mech-
anisms involved is still very limited. In addition, little is
known of the in vivo fate of the stem cells and the po-
tential disparities between the different cell sources. This
seems important as it may ultimately determine which stem
cell source might be most advantageous for future clinical
translation.
Overall, heart valve tissue engineering represents a prom-
ising approach for functional autologous cell-based re-
placements based on fully biodegradable materials. While
the in vitro heart valve tissue engineering approach offers
more mature implants with better immediate functionality,
the in situ approach offers a less complex alternative with
potentially higher clinical feasibility. Therefore, paediatric
patients in particular would benefit from these replacement
structures suited to repair of congenital heart defects. But
a constantly increasing number of older patients with ac-
quired heart valve disease could also benefit from living re-
placement material with regenerative capacities and antith-
rombogenic surfaces. In this regard stem cells could offer
an easily accessible cell source with favourable expansion
capacities. Nevertheless, prior to final clinical implement-
ation of the heart valve tissue engineering concept, several
issues will have to be overcome on the experimental level
to ensure the safety of this promising technology.
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Figures (large format)
Figure 1
Available stem cells for heart valve tissue engineering. (A: Donor tissues and stem cell sources, B: Introduction of the cells into the in vitro heart
valve tissue engineering procedure; 1: cell isolation, 2: cell expansion, 3: seeding of cells onto the scaffold, 4: dynamic conditioning of the
construct in a bioreactor system, 5: possible implantation of the deriving construct into the patient).
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Figure 2
Bone marrow mononuclear cell-based tissue engineered heart valve prior to implantation into an animal model. (Reprinted from [23]: Weber B,
Scherman J, Emmert MY, Gruenenfelder J, Verbeek R, Bracher M, et al. Injectable living marrow stromal cell-based autologous tissue
engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J. 2011;32(22):2830–40. © Oxford University
Press, Oxford, UK, with kind permission.)
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Figure 3
Histomorphology of a chorionic villus showing the outer trophoblastic coverage surrounding the inner foetal mesenchyme also comprising the
foetal capillaries (black arrows). (Reprinted from: Weber B, Zeisberger SM, Hoerstrup SP. Prenatally harvested cells for cardiovascular tissue
engineering: Fabrication of autologous implants prior to birth. Placenta. 2011;32(Suppl. 4):S316–9. © Elsevier, Oxford, UK, with kind
permission).
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Figure 4
Human umbilical cord Wharton’s jelly-derived myofibroblast-like cells (WMFs) revealed smooth muscle-like phenotypes with positive stainings
for vimentin (C), desmin (E) and partially for α-sma (A) similar to mature vascular-derived myofibroblasts (B, D, F). (Reprinted from [48]: Weber
B, Schoenauer R, Papadopulos F, Modregger P, Peter S, Stampanoni M, et al. Engineering of living autologous human umbilical cord cell-based
septal occluder membranes using composite PGA-P4HB matrices. Biomaterials. 2011;32(36):9630–41. © Elsevier, Oxford, UK, with kind
permission.)
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